Diamyd Medical

Diamyd Medical is a Swedish clinical-stage diabetes company developing therapies using the in-licensed substances GAD and GABA for the prevention or treatment of diabetes and other serious inflammatory diseases.

Two disease-modifying therapies are being developed, the antigen-specific immunotherapy Diamyd® and the oral regenerative and immunomodulatory therapy Remygen®.

Diamyd Medical’s shares are traded on Nasdaq First North, ticker DMYD B.